Giant Cell Tumor of Bone

Giant cell tumor (GCT) of bone is a benign but locally aggressive neoplasm characterized by proliferation of mononuclear stromal cells (the neoplastic component) and abundant osteoclast-like multinucleated giant cells. Despite benign histology, GCT demonstrates aggressive local behavior with high recurrence rates (10-50%) and rare metastatic potential (1-5% pulmonary metastases).

Definition

GCT is defined as a primary bone tumor composed of three cell populations: (1) mononuclear histiocyte-like cells, (2) mononuclear spindle-shaped stromal cells (the neoplastic component with H3F3A mutations), and (3) multinucleated osteoclast-like giant cells containing 20-100 nuclei per cell. The tumor characteristically arises in the epiphysis of long bones after physeal closure.

Incidence

• Annual incidence: 1 per million population
• Comprises 5% of all primary bone tumors
• Represents 20% of benign bone tumors
• Accounts for 18% of all bone tumors biopsied
• Rare in children (under 2% before physeal closure)

Clinical Presentation

The classic presentation is progressive pain localized to the involved bone, often for several months before diagnosis. Pain is typically activity-related initially, then becomes constant. Swelling may be present if the lesion is superficial. Pathological fracture occurs in 10-20% of cases.

Physical Examination

Differential Diagnosis

The epiphyseal lytic lesion of GCT overlaps radiologically and histologically with several other giant cell-rich and lytic bone lesions. Age, exact location, biochemistry and H3F3A status are the key discriminators.

Immediate Postoperative Management

Surveillance Protocol

Functional Outcomes

Recurrence Rates by Treatment

Global Epidemiology

Giant cell tumour of bone (GCT) is consistently reported as roughly 4-5% of all primary bone tumours and around 20% of benign bone tumours worldwide, with an estimated incidence of approximately 1 per million population per year. A long-recognised geographic pattern is a relatively higher proportion in East and South Asian series (where GCT can account for up to 20% of primary bone tumours) compared with Western series, with a peak in the third to fourth decade and a slight female predominance. Single-institution and pooled series (Rizzoli, Mayo, UK and Asian sarcoma centres) consistently localise about 85% of lesions to around the knee, with the distal radius and sacrum the most common non-knee sites.

Side-by-Side Guidance & Consensus

Registry & Real-World Evidence

There is no dedicated international GCT registry; population-level estimates derive from national bone-tumour and sarcoma registries (e.g. the Netherlands Cancer Registry, the UK National Cancer Registration and Analysis Service, and the Rizzoli and Mayo institutional databases) and from the pooled denosumab trial programme (NCT00680992). These data sources underpin the convergent ~1 per million incidence figure and the recognition that recurrence after curettage following denosumab may exceed that of curettage with adjuvants alone, as summarised by van der Heijden et al (Curr Opin Oncol 2020).

Practice Variation & Access

Practice variation is greatest around denosumab (duration of neoadjuvant therapy, and whether to use it at all in resectable disease) and around reconstruction after resection (endoprosthesis vs allograft vs arthrodesis), reflecting differing drug access, reimbursement and surgical resources. In Australia, denosumab is PBS-listed under Authority Required for unresectable, recurrent-inoperable or metastatic GCT with histological confirmation and specialist management; loading doses are given on days 1, 8, 15 and 29 followed by 120 mg subcutaneously every 4 weeks, with calcium and vitamin D supplementation to prevent hypocalcaemia. Across all systems, outcomes are best when GCT is managed within a specialist sarcoma multidisciplinary team with structured long-term surveillance.